Decoy Therapeutics (DCOY) Competitors

$7.30 0.00 (0.00%)

Closing price 05/22/2026 03:54 PM Eastern

Extended Trading

$7.70 +0.40 (+5.47%)

As of 05/22/2026 07:57 PM Eastern

DCOY vs. NCNA, GNPX, PMCB, ADXN, and CURX

Should you buy Decoy Therapeutics stock or one of its competitors? MarketBeat compares Decoy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Decoy Therapeutics include NuCana (NCNA), Genprex (GNPX), Nuvilex (PMCB), Addex Therapeutics (ADXN), and Curanex Pharmaceuticals (CURX). These companies are all part of the "pharmaceutical products" industry.

How does Decoy Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

NuCana has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

NuCana is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, Decoy Therapeutics had 2 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for NuCana. NuCana's average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Decoy Therapeutics	Neutral

44.0% of NuCana shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 0.3% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NuCana's return on equity of -153.61% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NuCana and Decoy Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Genprex?

Genprex (NASDAQ:GNPX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Genprex has a beta of -0.94, meaning that its stock price is 194% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Genprex's return on equity of -247.32% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Decoy Therapeutics	N/A	-395.42%	-193.30%

In the previous week, Decoy Therapeutics had 2 more articles in the media than Genprex. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Genprex. Genprex's average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genprex	Neutral
Decoy Therapeutics	Neutral

14.1% of Genprex shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 0.3% of Genprex shares are held by insiders. Comparatively, 0.3% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Decoy Therapeutics beats Genprex on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Nuvilex?

Decoy Therapeutics (NASDAQ:DCOY) and Nuvilex (NASDAQ:PMCB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Decoy Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Nuvilex's return on equity of 2.13% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Nuvilex	N/A	2.13%	1.69%

Nuvilex is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Decoy Therapeutics had 2 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Nuvilex. Decoy Therapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Nuvilex	Neutral

Summary

Nuvilex beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 0.3% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Addex Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Addex Therapeutics has higher revenue and earnings than Decoy Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	41.56	$8.02M	-$5.74	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Addex Therapeutics' return on equity of -80.69% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-80.69%	-69.69%
Decoy Therapeutics	N/A	-395.42%	-193.30%

In the previous week, Decoy Therapeutics had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Decoy Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Addex Therapeutics beats Decoy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Curanex Pharmaceuticals?

Decoy Therapeutics (NASDAQ:DCOY) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Curanex Pharmaceuticals' return on equity of -85.41% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Decoy Therapeutics and Decoy Therapeutics both had 2 articles in the media. Decoy Therapeutics' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curanex Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Decoy Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Decoy Therapeutics beats Curanex Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.88M	$927.43M	$4.26B	$12.34B
Dividend Yield	N/A	4.84%	5.93%	5.28%
P/E Ratio	-0.07	1.46	21.90	25.66
Price / Sales	N/A	119.63	180.61	86.31
Price / Cash	N/A	20.07	55.68	56.67
Price / Book	1.00	7.59	34.85	7.14
Net Income	-$12.52M	-$3.64M	$112.32M	$335.98M
7 Day Performance	37.74%	3.01%	3.55%	4.15%
1 Month Performance	33.72%	76.62%	3.59%	2.54%
1 Year Performance	N/A	126.61%	15.80%	35.06%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	1.92 of 5 stars	$7.30 flat	$30.00 +311.0%	N/A	$3.88M	N/A	N/A	20	Positive News
NCNA NuCana	0.2065 of 5 stars	$2.18 +10.1%	N/A	-73.4%	$9.07M	N/A	N/A	30	Positive News High Trading Volume
GNPX Genprex	0.2862 of 5 stars	$0.83 -3.6%	N/A	-94.0%	$8.65M	N/A	N/A	20
PMCB Nuvilex	0.4335 of 5 stars	$0.80 -15.4%	N/A	-21.1%	$8.64M	N/A	N/A	4	Positive News High Trading Volume
ADXN Addex Therapeutics	0.6861 of 5 stars	$7.02 +3.0%	N/A	-14.3%	$8.63M	$460K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. NCNA, GNPX, PMCB, ADXN, and CURX

How does Decoy Therapeutics compare to NuCana?

Summary

How does Decoy Therapeutics compare to Genprex?

Summary

How does Decoy Therapeutics compare to Nuvilex?

Summary

How does Decoy Therapeutics compare to Addex Therapeutics?

Summary

How does Decoy Therapeutics compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. NCNA, GNPX, PMCB, ADXN, and CURX

How does Decoy Therapeutics compare to NuCana?

Which has more risk & volatility, NCNA or DCOY?

Which has better earnings and valuation, NCNA or DCOY?

Does the media favor NCNA or DCOY?

Do institutionals and insiders believe in NCNA or DCOY?

Is NCNA or DCOY more profitable?

Do analysts recommend NCNA or DCOY?

Summary

How does Decoy Therapeutics compare to Genprex?

Which has higher earnings & valuation, GNPX or DCOY?

Which has more volatility & risk, GNPX or DCOY?

Is GNPX or DCOY more profitable?

Does the media favor GNPX or DCOY?

Do institutionals & insiders believe in GNPX or DCOY?

Do analysts prefer GNPX or DCOY?

Summary

How does Decoy Therapeutics compare to Nuvilex?

Which has more risk and volatility, DCOY or PMCB?

Is DCOY or PMCB more profitable?

Which has better valuation & earnings, DCOY or PMCB?

Do analysts prefer DCOY or PMCB?

Do insiders & institutionals have more ownership in DCOY or PMCB?

Does the media prefer DCOY or PMCB?

Summary

How does Decoy Therapeutics compare to Addex Therapeutics?

Do analysts prefer ADXN or DCOY?

Do institutionals and insiders have more ownership in ADXN or DCOY?

Which has more risk & volatility, ADXN or DCOY?

Which has higher valuation and earnings, ADXN or DCOY?

Is ADXN or DCOY more profitable?

Does the media prefer ADXN or DCOY?

Summary

How does Decoy Therapeutics compare to Curanex Pharmaceuticals?

Is DCOY or CURX more profitable?

Do institutionals & insiders have more ownership in DCOY or CURX?

Does the media prefer DCOY or CURX?

Which has better valuation and earnings, DCOY or CURX?

Do analysts prefer DCOY or CURX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools